FUCASO: Tus Revolutionary Tag Nrho-Human BCMA CAR-T Kev Kho Mob nrog Kev Ua Tau Zoo thiab Kev Nyab Xeeb
FUCASO, tsim los ntawm Nanjing IASO Biotechnology, yog ib qho kev kho mob CAR-T tshwj xeeb tsim los tsom rau B-cell maturation antigen (BCMA). Qhov kev kho no sawv tawm rau nws qhov kev ua tau zoo ntawm kev kho mob thiab kev nyab xeeb tsis sib xws, muab kev cia siab tshiab rau cov neeg mob rov qab los yog rov ua dua ntau yam myeloma (r / rMM). Pom zoo los ntawm National Medical Products Administration (NMPA) thaum Lub Rau Hli 30, 2023, FUCASO twb tau ua tiav qhov kev vam meej hauv kev kho mob.
Siab teb tus nqi: FUCASO boasts ib qho Tag Nrho Cov Lus Teb (ORR) ntawm 98.9% thiab Kev Teb Ua tiav (CR) tus nqi ntawm 82.4%, ntau dua li lwm cov kev kho mob muaj.
Kev zam txim ntev: Cov neeg mob kho nrog FUCASO tau qhia txog 12-hli Progression-Free Survival (PFS) tus nqi ntawm 85.5%, qhia txog kev tshem tawm mus ntev thiab txhim kho lub neej zoo.
Kev ruaj ntseg Profile: Nrog ≥3 qib Cytokine Release Syndrome (CRS) tshwm sim nyob rau hauv tsuas yog 1% ntawm cov neeg mob thiab tsis muaj cov ntaub ntawv qhia txog ≥3 qib Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), FUCASO muaj kev kho mob zoo dua piv rau lwm cov kev kho mob CAR-T .
Nqi-zoo: FUCASO kev kho mob raug nqi tsawg dua li cov kev kho mob zoo sib xws muaj nyob hauv Tebchaws Meskas, ua rau nws muaj kev xaiv zoo rau ntau tus neeg mob.
Ntiaj teb no ncav cuag: IASO BIO tau tsim ib lub chaw kho mob thoob plaws hauv Suav teb, muaj peev xwm pab cov neeg mob los ntawm thoob plaws ntiaj teb nrog kev pabcuam kev sib tham los ntawm kev sib tham txog kev kho mob tom qab.
Thawj tus neeg mob tau kho nrog FUCASO tau ua tiav tsib xyoos ntawm kev muaj sia nyob tsis muaj mob qog noj ntshav, qhov tseem ceeb tshaj plaws piv rau qhov nruab nrab ntawm Kev Tiv Thaiv-Free Survival (PFS) tsuas yog 2.9 lub hlis nrog kev saib xyuas tus qauv. Qhov no qhia txog FUCASO lub peev xwm los hloov kho thaj chaw kho mob rau ntau yam myeloma.